CS
NTLA icon

Candriam SCA’s Intellia Therapeutics NTLA Stock Holding History

Candriam SCA’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-91,275
Closed -$2.78M – 721
2023
Q4 		$2.78M Buy
91,275
+40,000
+78% +$1.15M 0.02% 433
2023
Q3 		$1.62M Sell
51,275
-40,000
-44% -$1.55M 0.01% 479
2023
Q2 		$3.72M Hold
91,275
– – 0.03% 383
2023
Q1 		$3.13M Hold
91,275
– – 0.02% 470
2022
Q4 		$3.18M Sell
91,275
-50,000
-35% -$2.38M 0.02% 485
2022
Q3 		$7.91M Hold
141,275
– – 0.06% 315
2022
Q2 		$7.31M Buy
141,275
+40,148
+40% +$2.04M 0.06% 273
2022
Q1 		$7.35M Hold
101,127
– – 0.05% 296
2021
Q4 		$12M Hold
101,127
– – 0.08% 238
2021
Q3 		$13.6M Hold
101,127
– – 0.09% 229
2021
Q2 		$16.4M Sell
101,127
-81,790
-45% -$6.37M 0.11% 214
2021
Q1 		$9.56M Hold
182,917
– – 0.08% 255
2020
Q4 		$9.95M Buy
+182,917
New +$6.64M 0.08% 261
2019
Q4 		– Sell
-120,000
Closed -$1.6M – 802
2019
Q3 		$1.6M Hold
120,000
– – 0.02% 534
2019
Q2 		$1.96M Hold
120,000
– – 0.02% 523
2019
Q1 		$2.05M Hold
120,000
– – 0.03% 493
2018
Q4 		$1.64M Hold
120,000
– – 0.03% 500
2018
Q3 		$3.43M Buy
120,000
+20,300
+20% +$591K 0.05% 392
2018
Q2 		$2.73M Buy
99,700
+19,700
+25% +$477K 0.04% 416
2018
Q1 		$1.69M Buy
80,000
+15,000
+23% +$369K 0.03% 509
2017
Q4 		$1.25M Buy
+65,000
New +$1.5M 0.02% 547

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Candriam SCA's NTLA Position: Q1 2024 in Review

Candriam SCA sold out of Intellia Therapeutics (NTLA) in Q1 2024, closing a stake of 91,275 shares — an estimated $2.78M sold.

Candriam SCA first reported a position in NTLA in Q4 2017 and held it in 21 quarters. The position peaked at $16.4M in Q2 2021. 285 funds tracked by Wall St. Rank hold NTLA as of Q1 2024.

  • Candriam SCA reported no remaining Intellia Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Candriam SCA sold 91,275 Intellia Therapeutics shares in Q1 2024, an estimated $2.78M.
  • Candriam SCA first reported a position in Intellia Therapeutics in Q4 2017 and held it in 21 quarters.
  • Candriam SCA's Intellia Therapeutics position peaked at $16.4M in Q2 2021.
  • 285 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2024.

Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.